Casanovas-Marsal Josep-Oriol, Morales Hijazo Lorena, Grima Campos Laura, Calvo Sanz Vanesa, Fernández Castro Belén, González de la Cuesta Delia
Enfermero, Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón. Zaragoza. España.
Enfermera, Hospital de Día de Oncología, Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón. Zaragoza. España.
Rev Esp Salud Publica. 2023 Feb 1;97:e202302008.
Peripheral neuropathy and onycholysis are adverse events produced by taxanes in breast cancer that persist even after the end of treatment and negatively influence quality of life. The objectives of the study were to describe these side effects and the degree of involvement and relating them to the drug doses received.
Prospective, cross-sectional study of in 50 womens dignosed of breast cancer, treated with docetaxel and paclitaxel in Hospital Universitario Miguel Servet in Zaragoza (Aragón, Spain). CTCAE v.5.0 scale and Semes Weinsten test were used to evaluate peripheral neuropathy and onycholysis. ECOG scale was performed to measure the health-related quality of life. Study variables were evaluated before-during treatment and 1 and 6 months after finish treatment. Statistical analysis was performed using Jamovi 1.2®. For the relationship of the qualitative variables, the chi-square, Fisher's exact test, Mc's test were used. Nemar and the Odds Ratio test. Effects were considered significant if p<0.05.
43 subjects were included. During treatment the 9.8 presented motor neuropathy and 12.2% sensitive neuropathy, 37.2% onycholisis in upper extremities and 39.5% in lower extremities (χ=11.3; p<0.001 / χ=13.0; p<0.001) and 38.1% a health related quality of live limited in excessive activities (χ=10.3; p=0.001). Post-treatment evaluation the 20.9% presented motor neuropathy and 32.6% sensitive neuropathy (χ=3.57; p=0.059 / χ=6.23; p=0.013), the 86% onycholisis in upper extremities and lower extremities (χ=6.07; p=0.048 / χ=10.1; p=0.006) and 58.5% a health related quality of live limited in excessive activities (χ=8.47; p=0.014). 6 month later, the initials parameters were not recuperated.
Taxanes have a negative impact on the health-related quality of life in patients, even 6 months after finishing treatment due to the peripheral neuropathy and onycholysis that they cause.
外周神经病变和甲脱离是紫杉烷类药物治疗乳腺癌时产生的不良事件，即使在治疗结束后仍会持续存在，并对生活质量产生负面影响。本研究的目的是描述这些副作用及其受累程度，并将它们与所接受的药物剂量相关联。
在西班牙阿拉贡自治区萨拉戈萨市米格尔·塞尔维特大学医院，对50例诊断为乳腺癌并接受多西他赛和紫杉醇治疗的女性进行前瞻性横断面研究。采用CTCAE v.5.0量表和Semes Weinsten试验评估外周神经病变和甲脱离。采用ECOG量表测量健康相关生活质量。在治疗前、治疗期间以及治疗结束后1个月和6个月对研究变量进行评估。使用Jamovi 1.2®进行统计分析。对于定性变量之间的关系，使用卡方检验、Fisher精确检验、Mc检验、Nemar检验和优势比检验。如果p<0.05，则认为效应具有显著性。
纳入了43名受试者。治疗期间，9.8%出现运动神经病变，12.2%出现感觉神经病变，37.2%上肢出现甲脱离，39.5%下肢出现甲脱离（χ=11.3；p<0.001/χ=13.0；p<0.001），38.1%与健康相关的生活质量在过度活动方面受到限制（χ=10.3；p=0.0
